Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Adaptive Biotechnologies Corp | adpt-ex322_177.htm |
| EX-32.1 - EX-32.1 - Adaptive Biotechnologies Corp | adpt-ex321_176.htm |
| EX-31.2 - EX-31.2 - Adaptive Biotechnologies Corp | adpt-ex312_179.htm |
| EX-31.1 - EX-31.1 - Adaptive Biotechnologies Corp | adpt-ex311_178.htm |
| EX-21.1 - EX-21.1 - Adaptive Biotechnologies Corp | adpt-ex211_175.htm |
| EX-10.17 - EX-10.17 - Adaptive Biotechnologies Corp | adpt-ex1017_339.htm |
| EX-10.16 - EX-10.16 - Adaptive Biotechnologies Corp | adpt-ex1016_340.htm |
| EX-10.12 - EX-10.12 - Adaptive Biotechnologies Corp | adpt-ex1012_218.htm |
| 10-K - 10-K - Adaptive Biotechnologies Corp | adpt-10k_20201231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
|
|
(1) |
Registration Statement (Form S-8 No. 333-232495) pertaining to the Sequenta Inc., 2008 Stock Plan, the Adaptive Biotechnologies Corporation 2009 Equity Incentive Plan, the Adaptive Biotechnologies Corporation 2019 Equity Incentive Plan and the Adaptive Biotechnologies Corporation 2019 Employee Stock Purchase Plan and |
|
|
(2) |
Registration Statement (Form S-3ASR No. 333-239854) of Adaptive Biotechnologies Corporation; |
of our reports dated February 24, 2021, with respect to the financial statements of Adaptive Biotechnologies Corporation, and the effectiveness of internal control over financial reporting of Adaptive Biotechnologies Corporation, included in this Annual Report (Form 10-K) for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Seattle, Washington
February 24, 2021